{"id":"NCT02474589","sponsor":"SIGA Technologies","briefTitle":"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat","officialTitle":"An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-19","primaryCompletion":"2016-08-24","completion":"2016-08-24","firstPosted":"2015-06-18","resultsPosted":"2017-11-28","lastUpdate":"2017-11-28"},"enrollment":449,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Smallpox"],"interventions":[{"type":"DRUG","name":"tecovirimat","otherNames":["ST-246"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.","primaryOutcome":{"measure":"To Determine the Number of Participants With Adverse Events","timeFrame":"45 days","effectByArm":[{"arm":"Active","deltaMin":134,"sd":null},{"arm":"Placebo","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":16,"exclusionCount":25},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["29972742"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":359},"commonTop":["Headache","Nausea","Diarrhoea","Dizziness","Fatigue"]}}